Xuanwu Hospital, Capital Medical University, Beijing, China.
Neurosurgery. 2013 May;72(5):730-8; discussion 730. doi: 10.1227/NEU.0b013e318285c1d3.
Although the majority of patients with cerebral venous sinus thrombosis (CVST) obtain an optimistic clinical outcome after heparin or warfarin treatment, there remains a subgroup of patients who do not respond to conventional anticoagulation treatment. These patients, especially younger people, as documented by hospital-based studies, have a high morbidity and mortality rate.
To verify the safety and efficacy of a dual mechanical thrombectomy with thrombolysis treatment modality option in patients with severe CVST.
Fifty-two patients diagnosed with CVST were enrolled and treated with mechanical thrombectomy combined with thrombolysis. Patients underwent urokinase 100 to 1500 × 10 IU intravenous sinus injection via a jugular catheter after confirming diagnoses of CVST by using either magnetic resonance imaging/magnetic resonance venography or digital subtract angiography. Information obtained on the patients included recanalization status of venous sinuses as evaluated by magnetic resonance venography or digital subtract angiography at admission, during operation, and at 3- and 6-month follow-up after treatment.
The percentage of patients that showed complete and partial recanalization were 87% and 6%, respectively, after mechanical thrombectomy combined with thrombolysis treatment; 8% of the patients showed no recanalization. The modified Rankin Scale scores were 1.0 ± 0.9, 0.85 ± 0.63, and 0.37 ± 0.53 for discharge, and 3- and 6-month follow-up, respectively. A total of 6 patients died despite receiving aggressive treatment. No cases of relapse occurred after 3 to 6 months of follow-up.
Thrombectomy combined with thrombolysis is a safe and valid treatment modality to use in severe CVST cases or in intractable patients that have shown no adequate response to antithrombotic drugs.
尽管大多数脑静脉窦血栓形成(CVST)患者在接受肝素或华法林治疗后获得了乐观的临床结果,但仍有一部分患者对常规抗凝治疗无反应。这些患者,尤其是年轻患者,正如医院为基础的研究所记录的那样,发病率和死亡率很高。
验证双重机械血栓切除术联合溶栓治疗方案在严重 CVST 患者中的安全性和有效性。
纳入 52 例 CVST 患者,采用机械血栓切除术联合溶栓治疗。通过颈内导管静脉窦内注射尿激酶 100 至 1500×10 IU,确认 CVST 诊断后,对患者进行治疗。通过磁共振成像/磁共振静脉造影或数字减影血管造影获得患者信息,包括入院时、手术期间和治疗后 3 至 6 个月的静脉窦再通情况。
机械血栓切除术联合溶栓治疗后,完全和部分再通的患者比例分别为 87%和 6%;8%的患者无再通。改良Rankin 量表评分在出院时、3 个月和 6 个月随访时分别为 1.0±0.9、0.85±0.63 和 0.37±0.53。尽管接受了积极治疗,但仍有 6 例患者死亡。在 3 至 6 个月的随访中,没有复发的病例。
在严重 CVST 病例或对抗血栓药物反应不佳的难治性患者中,血栓切除术联合溶栓是一种安全有效的治疗方法。